Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923531 · ClinicalTrials.gov registry record · Phase 1
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
A Phase 1 study, sponsored by X4 Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02923531 is a Phase 1 study that was terminated before completion, run by X4 Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT02923531, a Phase 1 study, was terminated before completion, sponsored by X4 Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.
Interventions
- DRUG Nivolumab
- DRUG X4P-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2018-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923531
The ClinicalTrials.gov registry entry for NCT02923531 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02923531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02923531 about?
NCT02923531 is a clinical study titled "Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma". The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiolo...
What is the current status of trial NCT02923531?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-12-07. Estimated completion is 2018-08-08.
What interventions are being tested in trial NCT02923531?
The interventions under investigation include: Nivolumab (DRUG), X4P-001 (DRUG).
Who is sponsoring clinical trial NCT02923531?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.